Compare Johnson & Johnson (JNJ) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs ProShares Ultra QQQ ETF — how do they compare? Johnson & Johnson trades at $249.44 (market cap $598.96B), while ProShares Ultra QQQ ETF trades at $89.26. The key difference: Johnson & Johnson pays a 2.15% dividend while ProShares Ultra QQQ ETF pays none. Which is the better fit depends on your goals.
| JNJ | QLD | |
|---|---|---|
Market Cap | $598.96B | — |
Volume | 6,156,228 | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $267.24 | $100.53 |
52-Week Low | $164.36 | $57.16 |
Enterprise Value | $631.90B | — |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
QLD, the ProShares Ultra QQQ ETF, trades at $86.06, up 0.17% on the day. The technical outlook is bearish, with moving averages signaling a downtrend and key support at $85. Recent articles highlight its long-term performance, with over 10,000% total return since inception, but caution its leveraged structure amplifies risks, evidenced by a historical maximum drawdown exceeding 63%.
The outlook for QLD is heavily tied to the performance of the Nasdaq-100 index. While leveraged exposure offers potential for amplified gains during tech rallies, the daily reset mechanism poses significant volatility and decay risks in choppy markets. Investor focus remains on upcoming tech earnings and broader market trends for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
